These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 10603320)
1. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. van der Most RG; Corver J; Strauss JH Virology; 1999 Dec; 265(1):83-95. PubMed ID: 10603320 [TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733 [TBL] [Abstract][Full Text] [Related]
3. Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus. Huang YJ; Nuckols JT; Horne KM; Vanlandingham D; Lobigs M; Higgs S Virol J; 2014 Mar; 11():60. PubMed ID: 24678844 [TBL] [Abstract][Full Text] [Related]
4. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Ryman KD; Xie H; Ledger TN; Campbell GA; Barrett AD Virology; 1997 Apr; 230(2):376-80. PubMed ID: 9143294 [TBL] [Abstract][Full Text] [Related]
5. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. Lee E; Lobigs M J Virol; 2008 Jun; 82(12):6024-33. PubMed ID: 18400851 [TBL] [Abstract][Full Text] [Related]
6. Yellow fever 17D virus: pseudo-revertant suppression of defective virus penetration and spread by mutations in domains II and III of the E protein. Vlaycheva L; Nickells M; Droll DA; Chambers TJ Virology; 2004 Sep; 327(1):41-9. PubMed ID: 15327896 [TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein locus involved in persistent infection and its effects on virus penetration and spread. Vlaycheva L; Nickells M; Droll DA; Chambers TJ J Gen Virol; 2005 Feb; 86(Pt 2):413-421. PubMed ID: 15659761 [TBL] [Abstract][Full Text] [Related]
9. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Ryman KD; Ledger TN; Campbell GA; Watowich SJ; Barrett AD Virology; 1998 Apr; 244(1):59-65. PubMed ID: 9581778 [TBL] [Abstract][Full Text] [Related]
10. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication. Silva PAGC; Molenkamp R; Dalebout TJ; Charlier N; Neyts JH; Spaan WJM; Bredenbeek PJ J Gen Virol; 2007 Jun; 88(Pt 6):1738-1747. PubMed ID: 17485534 [TBL] [Abstract][Full Text] [Related]
11. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. Nickells J; Cannella M; Droll DA; Liang Y; Wold WS; Chambers TJ J Virol; 2008 Dec; 82(24):12510-9. PubMed ID: 18842715 [TBL] [Abstract][Full Text] [Related]
12. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus. Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387 [TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. Vlaycheva LA; Chambers TJ J Virol; 2002 Jun; 76(12):6172-84. PubMed ID: 12021351 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Hahn CS; Dalrymple JM; Strauss JH; Rice CM Proc Natl Acad Sci U S A; 1987 Apr; 84(7):2019-23. PubMed ID: 3470774 [TBL] [Abstract][Full Text] [Related]
15. Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production. Lee E; Stocks CE; Amberg SM; Rice CM; Lobigs M J Virol; 2000 Jan; 74(1):24-32. PubMed ID: 10590087 [TBL] [Abstract][Full Text] [Related]
16. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus. Xie H; Ryman KD; Campbell GA; Barrett AD J Gen Virol; 1998 Aug; 79 ( Pt 8)():1895-9. PubMed ID: 9714237 [TBL] [Abstract][Full Text] [Related]
17. Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. Chambers TJ; Nickells M J Virol; 2001 Nov; 75(22):10912-22. PubMed ID: 11602731 [TBL] [Abstract][Full Text] [Related]
18. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. Bonaldo MC; Garratt RC; Caufour PS; Freire MS; Rodrigues MM; Nussenzweig RS; Galler R J Mol Biol; 2002 Jan; 315(4):873-85. PubMed ID: 11812154 [TBL] [Abstract][Full Text] [Related]
19. 17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein. Shiu SY; Morikawa S; Buckley A; Higgs S; Karunakarannair V; Blachere C; Gould EA J Gen Virol; 1991 Jun; 72 ( Pt 6)():1451-4. PubMed ID: 1710651 [TBL] [Abstract][Full Text] [Related]
20. Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes. Beasley DW; Morin M; Lamb AR; Hayman E; Watts DM; Lee CK; Trent DW; Monath TP Virus Res; 2013 Sep; 176(1-2):280-4. PubMed ID: 23602827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]